The MGC Pharmaceuticals Ltd (ASX: MXC) share price has been a strong performer on Thursday.
In morning trade the cannabis company’s shares have jumped 12% higher to 3.7 cents.
Why is the MGC Pharma share price jumping higher today?
Hot on the heels of a medicinal cannabis prescription update from Althea Group Holdings Ltd (ASX: AGH) on Wednesday, MGC Pharma released one of its own this morning.
According to the release, the company has now passed 2,000 prescriptions of its cannabinoid medicines in the UK, Australia, Brazil and Ireland. This follows the addition of 262 new patients during the month of December.
Management notes that this increase was driven by patient growth in Australia and the United Kingdom and supported by the recent approval of its products in Brazil and Ireland.
This is still some distance behind Althea. Yesterday it revealed that at the end of December its medicinal cannabis products had been prescribed to 4,018 patients. This meant Althea beat its year-end target of 4,000 prescriptions.
More to come in 2020.
MGC Pharma’s co-founder and managing director, Roby Zomer, was very pleased with the company’s performance in 2019.
He said: “MGC Pharma made terrific progress in 2019, having grown from just 100 prescriptions starting in August 2019, to more than 2,000 by the start of the calendar year.”
Mr Zomer appears confident that the company can build on this in 2020.
“I am confident that this rapid growth trajectory will continue in 2020 as our products are now available on three continents and the prescription numbers are projected to increase as the knowledge of MGC Pharma’s medicines improves amongst healthcare professionals,” he added.
“Last year we laid a very solid foundation for the Company and in 2020 we shall build on it as we plan to continue to grow product sales, expand distribution to new territories, advance our clinical trials and commence construction at our production facility in Malta. We expect a lot of near-term positive news flow and I look forward to updating our shareholders on our progress,” he concluded.
The post Why this ASX cannabis share jumped 12% higher today appeared first on Motley Fool Australia.
Whilst some of these cannabis companies could be worth watching, I would sooner buy these top growth shares that have the potential to smoke the market in the 2020s.
Our Motley Fool experts have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020